atai Life Sciences: Psychedelics, Mental Health, and Drug Development with Founder and Chairman Christian Angermayer After Earnings

In this episode, hosts Katie Perry and Austin Hankwitz explore atai Life Sciences with Founder and Chairman Christian Angermayer, covering its mission and the rise of mental health issues. Together, they discuss the current state of psychedelic regulation, atai’s drug development phases, how retail investors should approach Atai post-product launch, and the company’s go-to-market strategy.
$ATAI

00:00:00 START
00:01:20 What is atai Life Sciences?
00:08:55 The prevailing theory on the rapid rise of mental health issues
00:15:50 Regulatory bodies’ openness to collaborating with atai
00:17:58 The current state of the regulation process for psychedelics
00:19:17 Phases of drug development and where atai currently is
00:24:00 How retail investors should be thinking about atai once the products go live
00:27:10 atai’s go-to-market strategy
00:32:09 Current world leader who should have the psychedelic experience
00:35:28 What retail investors should be looking at in atai’s earnings
00:40:13 Longevity and anti-aging effects of psychedelics
After Earnings is brought to you by Stakeholder Labs and Morning Brew.

For more go to https://www.afterearnings.com
Follow Us
X: https://twitter.com/AfterEarnings
TikTok: https://www.tiktok.com/@AfterEarnings
Instagram: https://www.instagram.com/afterearnings_/
Reach Out
Email: afterearnings@morningbrew.com
Learn more about your ad choices. Visit megaphone.fm/adchoices